TY - JOUR
T1 - Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
AU - Passardi, Alessandro
AU - Cecconetto, Lorenzo
AU - Dall'Agata, Monia
AU - Dazzi, Claudio
AU - Pasquini, Enzo
AU - Oliverio, Giovanni
AU - Zumaglini, Federica
AU - Zoli, Wainer
AU - Nanni, Oriana
AU - Milandri, Carlo
AU - Frassineti, Giovanni Luca
AU - Amadori, Dino
PY - 2008/10/31
Y1 - 2008/10/31
N2 - Background: Docetaxel and gemcitabine combinations have proven active for the treatment of non-small cell lung cancer (NSCLC). The aim of the present study was to evaluate and compare two treatment schedules, one based on our own preclinical data and the other selected from the literature. Methods: Patients with stage IV NSCLC and at least one bidimensionally-measurable lesion were eligible. Adequate bone marrow reserve, normal hepatic and renal function, and an ECOG performance status of 0 to 2 were required. No prior chemotherapy was permitted. Patients were randomized to arm A (docetaxel 70 mg/m2on day 1 and gemcitabine 900 mg/m2 on days 3-8, every 3 weeks) or B (gemcitabine 900 mg/m2 on days 1 and 8, and docetaxel 70 mg/m2 on day 8, every 3 weeks). Results: The objective response rate was 20% (95% CI:10.0-35.9)and 18% (95% CI:8.6-33.9) in arms A and B, respectively. Disease control rates were very similar (54% in arm A and 53% in arm B). No differences were noted in median survival (32 vs. 33 weeks) or 1-year survival (33% vs. 35%). Toxicity was mild in both treatment arms. Conclusion: Our results highlighted acceptable activity and survival outcomes for both experimental and empirical schedules as first-line treatment of NSCLC, suggesting the potential usefulness of drug sequencing based on preclinical models.
AB - Background: Docetaxel and gemcitabine combinations have proven active for the treatment of non-small cell lung cancer (NSCLC). The aim of the present study was to evaluate and compare two treatment schedules, one based on our own preclinical data and the other selected from the literature. Methods: Patients with stage IV NSCLC and at least one bidimensionally-measurable lesion were eligible. Adequate bone marrow reserve, normal hepatic and renal function, and an ECOG performance status of 0 to 2 were required. No prior chemotherapy was permitted. Patients were randomized to arm A (docetaxel 70 mg/m2on day 1 and gemcitabine 900 mg/m2 on days 3-8, every 3 weeks) or B (gemcitabine 900 mg/m2 on days 1 and 8, and docetaxel 70 mg/m2 on day 8, every 3 weeks). Results: The objective response rate was 20% (95% CI:10.0-35.9)and 18% (95% CI:8.6-33.9) in arms A and B, respectively. Disease control rates were very similar (54% in arm A and 53% in arm B). No differences were noted in median survival (32 vs. 33 weeks) or 1-year survival (33% vs. 35%). Toxicity was mild in both treatment arms. Conclusion: Our results highlighted acceptable activity and survival outcomes for both experimental and empirical schedules as first-line treatment of NSCLC, suggesting the potential usefulness of drug sequencing based on preclinical models.
UR - http://www.scopus.com/inward/record.url?scp=56649099276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56649099276&partnerID=8YFLogxK
U2 - 10.1186/1479-5876-6-65
DO - 10.1186/1479-5876-6-65
M3 - Article
C2 - 18976450
AN - SCOPUS:56649099276
VL - 6
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
SN - 1479-5876
M1 - 65
ER -